D. E. Shaw & Co., Inc. Tango Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$6.52 - $12.01 $100,492 - $185,110	15,413 New	15,413 $152,000
Q4 2022 Feb 14, 2023	SELL	$3.41 - $8.29 $254,000 - $617,497	-74,487 Reduced 71.01%	30,404 $220,000
Q3 2022 Nov 14, 2022	SELL	$3.25 - $5.46 $235,706 - $395,986	-72,525 Reduced 40.88%	104,891 $380,000
Q2 2022 Aug 15, 2022	BUY	$3.86 - $8.01 $684,825 - $1.42 Million	177,416 New	177,416 $804,000

123

91.7M

3.1K

1.5K

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $275M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.